Weekly Anesthesiology Research Analysis
This week’s anesthesiology literature highlights high-quality trials and mechanistic advances that could change perioperative practice: a multicenter RCT (CREST‑MST) shows magnetic seizure therapy matches ultra‑brief unilateral ECT for depression with markedly better cognitive safety; mechanistic PNAS studies identify vagal TRPV3 as a peripheral mediator of sedative antistress effects and describe AI‑discovered multi‑subtype sodium‑channel blockers as promising nonopioid analgesics for periopera
Summary
This week’s anesthesiology literature highlights high-quality trials and mechanistic advances that could change perioperative practice: a multicenter RCT (CREST‑MST) shows magnetic seizure therapy matches ultra‑brief unilateral ECT for depression with markedly better cognitive safety; mechanistic PNAS studies identify vagal TRPV3 as a peripheral mediator of sedative antistress effects and describe AI‑discovered multi‑subtype sodium‑channel blockers as promising nonopioid analgesics for perioperative use. Together these findings push toward safer convulsive therapies, new peripheral targets for anxiolysis/sedation and next‑generation nonopioid analgesics, with immediate implications for anesthetic planning and neurocognitive risk management.
Selected Articles
1. Confirmatory efficacy and safety trial of magnetic seizure therapy versus right unilateral ultra-brief electroconvulsive therapy in depression (CREST-MST): a randomised, double-blind, non-inferiority trial in Canada and the USA.
In this multicenter, randomized, double‑blind non‑inferiority trial (n=239 randomized), magnetic seizure therapy (MST) achieved remission rates non‑inferior to right unilateral ultra‑brief ECT while producing substantially fewer autobiographical memory deficits and fewer treatment discontinuations due to adverse events.
Impact: Provides definitive, high‑quality evidence that MST can match ECT efficacy with markedly better cognitive safety, potentially changing first‑line convulsive therapy choices and anesthetic workflows for psychiatric ECT/MST services.
Clinical Implications: Anesthesia and psychiatry services should consider offering MST as an alternative to RUL‑UB ECT for patients prioritizing cognitive preservation; peri-procedural anesthesia workflows are similar but should plan for potentially different recovery and cognitive monitoring needs.
Key Findings
- MST remission rates were non-inferior to RUL-UB ECT (difference 5.3% favoring ECT; non-inferiority margin met).
- Autobiographical memory worsening was markedly lower with MST (2.7%) versus ECT (17.3%).
- Treatment discontinuations due to non-serious adverse events were more frequent with ECT (12 vs 3).
2. Vagal nerve TRPV3 regulates sedative-mediated appeasement.
Preclinical mechanistic work identifies TRPV3 in the nodose ganglion as a peripheral molecular sensor mediating the antistress and autonomic‑stabilizing effects of citronellal and sevoflurane via an NG→cNTS glutamatergic pathway; surgical vagotomy abolished these effects, establishing a causal vagal mechanism for sedative‑mediated appeasement.
Impact: Reveals a peripheral, targetable vagal mechanism for sedative and anxiolytic effects, opening translational opportunities to modulate perioperative autonomic responses and design adjunct anxiolytic strategies that avoid deeper CNS depression.
Clinical Implications: Suggests potential development of TRPV3‑directed agents or peripheral modulation strategies (pharmacologic or device‑based) to reduce perioperative stress responses and stabilize cardiopulmonary parameters without deep sedation.
Key Findings
- Citronellal and sevoflurane attenuated stress‑related heart and respiratory hyperactivity via TRPV3 in nodose ganglion.
- The NG→cNTS glutamatergic pathway was necessary for effects; surgical vagotomy abolished them.
- Identifies peripheral TRPV3 as a causal mediator of sedative/antistress autonomic effects.
3. The identification of potent nonopioid analgesics and their potential for perioperative use.
Using AI‑guided drug discovery and multi‑model validation, investigators developed multi‑subtype voltage‑gated sodium‑channel blockers that produce robust analgesia in rodent models without opioid‑typical adverse effects and demonstrated perioperative feasibility in a surgical simulation, proposing a translational path for potent nonopioid perioperative analgesics.
Impact: Challenges the paradigm that extreme subtype selectivity is required for safety, proposing an actionable multi‑target nonopioid analgesic strategy with clear perioperative implications for opioid‑sparing pathways.
Clinical Implications: If translated to humans, these agents could become potent opioid‑sparing perioperative analgesics, reducing opioid‑related respiratory and dependence risks; IND‑enabling safety (cardiac/CNS off‑target) and early phase perioperative trials are next steps.
Key Findings
- AI‑driven leads inhibit multiple analgesia‑related sodium channel subtypes effectively.
- Compounds produced robust analgesia across rodent pain models without opioid‑typical adverse effects.
- Perioperative surgical simulation supported feasibility for acute surgical pain applications.